全文获取类型
收费全文 | 119308篇 |
免费 | 10330篇 |
国内免费 | 6517篇 |
专业分类
耳鼻咽喉 | 997篇 |
儿科学 | 1336篇 |
妇产科学 | 1936篇 |
基础医学 | 16410篇 |
口腔科学 | 2538篇 |
临床医学 | 13481篇 |
内科学 | 20243篇 |
皮肤病学 | 1713篇 |
神经病学 | 7280篇 |
特种医学 | 4016篇 |
外国民族医学 | 47篇 |
外科学 | 14085篇 |
综合类 | 15655篇 |
现状与发展 | 18篇 |
一般理论 | 7篇 |
预防医学 | 7115篇 |
眼科学 | 3146篇 |
药学 | 11841篇 |
74篇 | |
中国医学 | 4361篇 |
肿瘤学 | 9856篇 |
出版年
2024年 | 231篇 |
2023年 | 1380篇 |
2022年 | 3142篇 |
2021年 | 4095篇 |
2020年 | 2921篇 |
2019年 | 2946篇 |
2018年 | 3445篇 |
2017年 | 2860篇 |
2016年 | 2860篇 |
2015年 | 4032篇 |
2014年 | 5129篇 |
2013年 | 4758篇 |
2012年 | 6815篇 |
2011年 | 7611篇 |
2010年 | 4456篇 |
2009年 | 3643篇 |
2008年 | 5170篇 |
2007年 | 5365篇 |
2006年 | 5346篇 |
2005年 | 4873篇 |
2004年 | 3542篇 |
2003年 | 3484篇 |
2002年 | 3052篇 |
2001年 | 6113篇 |
2000年 | 6120篇 |
1999年 | 5728篇 |
1998年 | 2559篇 |
1997年 | 2296篇 |
1996年 | 1596篇 |
1995年 | 1377篇 |
1994年 | 1209篇 |
1993年 | 888篇 |
1992年 | 2488篇 |
1991年 | 2151篇 |
1990年 | 1922篇 |
1989年 | 1837篇 |
1988年 | 1574篇 |
1987年 | 1421篇 |
1986年 | 1258篇 |
1985年 | 1028篇 |
1984年 | 669篇 |
1983年 | 516篇 |
1982年 | 269篇 |
1981年 | 220篇 |
1980年 | 162篇 |
1979年 | 310篇 |
1978年 | 77篇 |
1974年 | 75篇 |
1973年 | 95篇 |
1972年 | 71篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
Gui-Qi Zhu Ke-Qing Shi Sha Huang Gui-Qian Huang Yi-Qian Lin Zhi-Rui Zhou Martin Braddock Yong-Ping Chen Ming-Hua Zheng 《Medicine》2015,94(11)
Major ursodeoxycholic acid (UDCA)-based therapies for primary biliary cirrhosis (PBC) include UDCA only, or combined with either methotrexate (MTX), corticosteroids (COT), colchicine (COC), or bezafibrate (BEF). As the optimum treatment regimen is unclear and warrants exploration, we aimed to compare these therapies in terms of patient mortality or liver transplantation (MOLT) and adverse events (AE).PubMed, the Cochrane Library, and Scopus were searched for randomized controlled trials up to August 31, 2014. We estimated the hazard ratios (HRs) for MOLT and odds ratios (ORs) for AE. A sensitivity analysis based on the dose of UDCA was also executed.Thirty-one eligible articles were included. Compared with COT plus UDCA, UDCA (HR 0.38, 95% confidence interval [CI] 0.09–1.39), BEF plus UDCA (HR 0.29, 95% CI 0.02–4.83), COC plus UDCA (HR 0.39, 95% CI 0.07–2.25), MTX plus UDCA (HR 0.28, 95% CI 0.05–1.63), or OBS (HR 0.49, 95% CI 0.11–2.01) all provided an increased risk of MOLT. With respect to drug AE profile, although not differing appreciably, BEF plus UDCA was associated with more AEs compared with UDCA (OR 3.16, 95% CI 0.59–20.67), COT plus UDCA (OR 2.27, 95% CI 0.15–33.36), COC plus UDCA (OR 1.00, 95% CI 0.09–12.16), MTX plus UDCA (OR 2.03, 95% CI 0.23–17.82), or OBS (OR 3.00, 95% CI 0.53–20.75). The results of sensitivity analyses were highly consistent with previous analyses.COT plus UDCA was the optimal UDCA-based regimen for both MOLT and AEs. BEF plus UDCA was most likely to cause AEs, whereas monotherapy with UDCA and coadministriation of COT plus UDCA appeared to be associated with the fewest AEs for PBC treatment. 相似文献
4.
A mixed‐method study of effects of a therapeutic play intervention for children on parental anxiety and parents' perceptions of the intervention 下载免费PDF全文
5.
Platelet function has been described by many laboratory assays, and PL-11 is a new point-of-care platelet function analyzer based on platelet count drop method, which counts platelet before and after the addition of agonists in the citrated whole blood samples. The present study sought to compare PL-11 with other three major more established assays, light transmission aggregometry (LTA), VerifyNow? aspirin system and thromboelastography (TEG), for monitoring the short-term aspirin responses in healthy individuals. Ten healthy young men took 100?mg/d aspirin for 3-day treatment. Platelet function was measured via PL-11, LTA, VerifyNow and TEG, respectively. The blood samples were collected at baseline, 2 hour, 1 day during the aspirin treatment and 1 day, 5?±?1 days, 8?±?1 days after the aspirin withdrawal. Moreover, 90 additional healthy subjects were recruited to establish a reference range for PL-11. Platelet function of healthy subjects decreased significantly 2 hours after 100?mg/d aspirin intake and began to recover during 4–6 days after the aspirin withdrawal. Correlations between methods were PL-11 vs. LTA (r?=?0.614, p?<?0.01); PL-11 vs. VerifyNow (r?=?0.829, p?<?0.01); PL-11 vs. TEG (r?=?0.697, p?<?0.001). There was no significant bias between PL-11 and LTA at baseline (bias?=?1.94%, p?=?0.804) using Bland-Altman analysis, while the data of PL-11 were significantly higher than LTA (bias?=?24.02%, p?<?0.001) during the aspirin therapy. The reference range for PL-11 in healthy young individuals was from 66.8 to 90.5% (95%CI). When aspirin low-responsiveness was defined as LTA?>?20%, the cut-off values for each method were, respectively: PL-11?>?50%, VerifyNow?>?533 ARU, TEG?>?60.2%. The results of different platelet function assays were uninterchangeable for monitoring aspirin response and correlations among them were also varied. Correlations among PL-11 and other three major assays suggested the ability of PL-11 to assess the treatment effects of aspirin. But a large cohort study is needed to confirm the cut-off value of aspirin response detected by PL-11. 相似文献
6.
7.
朱晓东 《中国小儿急救医学》2020,(4):268-271
电阻抗断层成像技术(electrical impedance tomography,EIT)作为一项新兴的功能性成像技术,具有无损伤、便携、图像监护等突出特点。肺功能成像是目前EIT最主要的应用领域,可以实现实时动态监测肺通气及血流灌注。本文对肺EIT在儿童呼吸系统疾病及其诊疗过程中的应用基础及临床研究进展进行总结,为未来EIT技术在儿科临床急救领域的推广应用提供帮助。 相似文献
8.
Parallel enzyme‐linked immunosorbent assay screening for human immunodeficiency virus among blood donors in five Chinese blood centres: a retrospective analysis 下载免费PDF全文
9.
10.
目的研制加强型鼻咽通气道应用于五官科鼻腔手术后的气道管理。方法选取2014年1月至2015年3月行五官科鼻腔手术的患者60例,将其分为A组和B组,各30例。A组作为加强型鼻咽通气道组,术毕在膨胀止血海绵中放置加强型鼻咽通气道保留鼻腔通气;B组作为对照组,术毕采用传统单纯填塞膨胀止血海绵。通过术后24、48 h随访,对两组患者进行疼痛、睡眠质量、口干程度评分,并对其进行对比分析。结果加强型鼻咽通气道具有良好的抗压抗折性;A组患者24、48 h睡眠质量、口干程度评分均明显优于B组,差异均有统计学意义(P<0.05)。结论加强型鼻咽通气道用于五官科鼻腔手术后气道管理可增强气道管理安全性及患者舒适度。 相似文献